As of November 6, 2026, BridgeBio Pharma, Inc. is a publicly traded company (Nasdaq: BBIO). The largest holder reporting an active stake on Schedule 13D is Viking Global, at 5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Janus Henderson (6.8%), Farallon Capital Management, L.L.C. (5.5%), Dapice Joshua J. (5.2%) (Schedule 13D/A, July 10, 2026).
Is this your company?
About to sign with, pay or invest in BridgeBio Pharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BridgeBio Pharma, Inc. a real, registered company?
- BridgeBio Pharma, Inc. files with the SEC under CIK 1743881 (its SEC filings).
- Its shares are listed under the ticker BBIO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Palo Alto, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BridgeBio Pharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Randal W. Scott, Director (Form 8-K filed 2026-06-26). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are BridgeBio Pharma, Inc.'s owners and officers?
BridgeBio Pharma, Inc.: incorporated in Delaware; business address in Palo Alto, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.1% |
| Schedule 13D/A, 2026-08-17 | Kkr Genetic Disorder L.P. | 4.7% |
| Schedule 13G/A, 2026-08-03 | Farallon Capital Management, L.L.C. | 5.5% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 4.96% |
| Schedule 13D/A, 2026-07-10 | Viking Global Investors LP | 5% |
| Schedule 13G, 2026-05-29 | Dapice Joshua J. | 5.2% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 6.8% |
| Schedule 13G/A, 2026-04-16 | Neil Kumar | 4.6% |
| Schedule 13D/A, 2026-04-02 | Viking Global Investors LP | 6.1% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-17 | Janus Henderson Group PLC | 5.7% |
| Schedule 13D/A, 2026-02-17 | Viking Global Investors LP | 6.8% |
Questions about who owns BridgeBio Pharma, Inc.
Who owns BridgeBio Pharma, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of BridgeBio Pharma, Inc.: Janus Henderson Group PLC (6.8%, Schedule 13G/A, filed 2026-05-15), Farallon Capital Management, L.L.C. (5.5%, Schedule 13G/A, filed 2026-08-03), Dapice Joshua J. (5.2%, Schedule 13G, filed 2026-05-29), Blackrock, Inc. (5.1%, Schedule 13G, filed 2026-10-27) and Viking Global Investors LP (5%, Schedule 13D/A, filed 2026-07-10).
Who are the largest shareholders of BridgeBio Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of BridgeBio Pharma, Inc. on this page are Janus Henderson Group PLC (6.8%), Farallon Capital Management, L.L.C. (5.5%) and Dapice Joshua J. (5.2%).
When did Janus Henderson Group PLC buy into BridgeBio Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G, filed 2026-02-17, reporting 5.7%; its latest, Schedule 13G/A filed 2026-05-15, reports 6.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BridgeBio Pharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BridgeBio Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BridgeBio Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-26 | Randal W. Scott | Director | departed | 2026-06-22 |
Which insiders own BridgeBio Pharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 18,555,375 shares (9.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- Viking Global Opportunities Portfolio GP LLC, a 10% owner: 18,555,375 shares (9.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- , a 10% owner: 18,555,375 shares (9.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- Viking Global Opportunities Illiquid Investments Sub-Master LP, a 10% owner: 18,555,375 shares (9.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
- , a 10% owner: 18,555,375 shares (9.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-07-01).
Shares outstanding: 194,800,782 as of 2026-10-22, from the company's latest SEC cover page.
How much has BridgeBio Pharma, Inc. raised?
No fundraising or offering filing from BridgeBio Pharma, Inc. is on file with us.
Keep reading
More on BridgeBio Pharma, Inc. and the records around it.
BridgeBio Pharma, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026), Tyra Biosciences, Inc. (May 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bridgebio-pharma